Immunohistochemical Stain - HER-2/neu

The Immunohistochemical Stain – HER-2/neu is a specialized diagnostic test designed to detect and evaluate HER-2/neu protein expression in tissue samples. This test plays a pivotal role in the diagnosis, prognosis, and treatment planning for cancers such as breast and gastric carcinomas. By utilizing advanced immunohistochemical (IHC) methodology, it provides critical insights into the molecular characteristics of tumors, enabling personalized therapeutic decisions and improving patient outcomes.

Why You Need This Test

The HER-2/neu protein is a key biomarker in oncology, particularly in breast and gastric cancers. Overexpression or amplification of HER-2/neu is associated with aggressive tumor behavior and poor prognosis. This test is essential for identifying patients who may benefit from HER-2-targeted therapies, such as trastuzumab or pertuzumab, which have been shown to significantly improve survival rates. By determining HER-2/neu status, this test helps oncologists tailor treatment plans, ensuring that patients receive the most effective therapies for their specific cancer type.

Symptoms That Indicate This Test

This test is recommended for individuals presenting with symptoms or conditions suggestive of breast or gastric cancer. These may include:

• A palpable lump in the breast or changes in breast size, shape, or texture.
• Nipple discharge or inversion.
• Unexplained weight loss, abdominal pain, or difficulty swallowing, which may indicate gastric cancer.
• A family history of HER-2-positive cancers.
• Recurrence or progression of previously diagnosed cancer.

Natural Production

HER-2/neu, also known as human epidermal growth factor receptor 2, is a protein naturally expressed on the surface of certain cells. It plays a role in cell growth and repair. In normal conditions, HER-2/neu levels are tightly regulated. However, genetic mutations or amplifications can lead to overexpression, contributing to uncontrolled cell proliferation and tumor development. Factors such as genetic predisposition and environmental influences may affect HER-2/neu expression, making this test crucial for identifying abnormalities.

What Happens If Untreated

Ignoring abnormal HER-2/neu test results can have serious consequences. Overexpression of HER-2/neu is linked to aggressive tumor growth, increased risk of metastasis, and resistance to conventional therapies. Without targeted treatment, patients may experience rapid disease progression, reduced quality of life, and lower survival rates. Early detection and intervention are critical to improving outcomes and preventing complications.

How to Prepare for the Test

No special preparation is required for this test. However, it is important to provide your healthcare provider with a detailed medical history, including any prior cancer diagnoses or treatments. If you are undergoing a biopsy or surgery to obtain the tissue sample, follow your doctor’s instructions regarding fasting or medication adjustments.

Test Overview

The test involves applying specific antibodies to the tissue sample, which bind to the HER-2/neu protein. A chromogenic detection system is used to visualize the interaction, allowing pathologists to assess HER-2/neu expression under a microscope. The results are reported as negative, equivocal, or positive, guiding further diagnostic and therapeutic decisions.

Product Categories

This test is categorized under Cytology and Histopathology, making it an essential resource for laboratories and healthcare providers specializing in cancer diagnostics and molecular pathology.

The Immunohistochemical Stain – HER-2/neu is a reliable and high-performance diagnostic solution, offering precise detection of HER-2/neu protein expression. With its advanced methodology, compatibility with standard laboratory workflows, and timely results, this test is indispensable for accurate cancer diagnosis, prognosis, and treatment planning.